Concepedia

Christopher R. Wellaway

CR

Statistics

Publications

8

Citations

747

H-Index

8

Active since

2017

Affiliations

GlaxoSmithKline (United Kingdom)(Current)

Peter MacCallum Cancer Centre

University of Strathclyde

University of Glasgow

The University of Melbourne

Christopher R. Wellaway is an author at GlaxoSmithKline (United Kingdom) specializing in natural sciences, biochemistry, and drug discovery.

ORCID

Top concepts

Publications per year

2017–2022

8

Publications

8

Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation

Omer Gilan, Inmaculada Rioja, Kathy Knezevic et al. · Science · 2020 · 411 citations · Full text

Click chemistry enables preclinical evaluation of targeted epigenetic therapies

Dean Tyler, Johanna Vappiani, Tatiana Cañeque et al. · Science · 2017 · 140 citations · Full text

Discovery of a Bromodomain and Extraterminal Inhibitor with a Low Predicted Human Dose through Synergistic Use of Encoded Library Technology and Fragment Screening

Christopher R. Wellaway, Dominique Amans, Paul Bamborough et al. · Journal of Medicinal Chemistry · 2020 · 69 citations · Full text

Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype

Christopher R. Wellaway, Paul Bamborough, Sharon G. Bernard et al. · Journal of Medicinal Chemistry · 2020 · 46 citations · Full text

, , +17

Conformationally rigid pyrazoloquinazoline α-amino acids: one- and two-photon induced fluorescence

Jonathan D. Bell, Alexander H. Harkiss, David Nobis et al. · Chemical Communications · 2020 · 27 citations · Full text

, , +14

1–5 of 8